Searched for
PATENT EXPIRATION
'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugsDespite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...- Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...
- Pfizer CFO Dave Denton to leave company in AugustPfizer's finance chief Dave Denton is leaving on August 15. Cecile Guegan will be the interim chief financial officer. Denton's departure r...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- The hidden cost of looking better: What health insurance covers, and what it leaves you to payRising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...
- Hetero partners with Richter to develop, market Semaglutide injection globallyHyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...
- If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil KhorakiwalaWockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected t...
- Profit on paper, loss in reality: How a routine accounting tool is used to deceive and take investors for a rideAmortisation is a number most investors skip, but it can shape reported profit. On the surface, it looks routine: A company spreads the cos...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- Hindustan Labs, RK Steel get Sebi nod to launch IPOsHindustan Laboratories has received Sebi's observations, a crucial step towards its IPO, which includes a fresh issue and an offer for sale...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Delhi HC clears Zydus to sell biosimilar of BMS cancer drug NivolumabThe Delhi High Court has permitted Zydus Lifesciences to produce and market a biosimilar cancer drug. This decision comes as the patent for...
- Delhi HC allows Sun Pharma to manufacture, export its own weight loss drugThe Delhi High Court has allowed Sun Pharma to manufacture and export its version of semaglutide, the diabetes and anti-obesity drug made b...
- Dr Reddy’s gets nod to make generic semaglutide for weight lossDr Reddy's Laboratories is set to launch generic semaglutide, a popular weight loss drug. An expert committee has approved their proposal. ...
- Bristol Myers to buy Mirati for $4.8 billionThe purchase will give a boost to Bristol as patent expirations weigh on sales of its oncology medicines. The company had to slash its reve...
- 3D printing may turn cheap as patents expireA bunch of 3D printing patents expiring this year are likely to open up opportunities for Indian entrepreneurs to build more efficient.
- 3D printing may turn cheap as patents expireMany are eagerly waiting for the patents to expire later this year. The market will likely see another round of hectic innovations.
- Sun Pharma takes Novartis to US Court, seeks permission to market Glivec in USUntil and unless Sun obtains a court decision of non-infringement and/or invalidity on the ’051 patent, it faces the risk of patent infring...
- Dr Reddy's Laboratories wins round 1 of patent warUS court dismisses one of the three patent claims made by Roche for Boniva; DRL still in litigation for two other listed patents.
Load More
